Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oxaliplatin in practice

J L Misset1

  • 1SMST Hôpital Paul Brousse, Villejuif, France.

British Journal of Cancer
|July 1, 1998
PubMed
Summary
This summary is machine-generated.

Oxaliplatin is an effective platinum-based chemotherapy for colorectal and ovarian cancers. It shows a favorable safety profile with manageable side effects, making it suitable for combination therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.

British journal of cancer·2011
Same author

What is an "elderly" oncologic patient?

Critical reviews in oncology/hematology·2008
Same author

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.

British journal of cancer·2006
Same author

Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2004
Same author

[Does primary chemotherapy really increase the rate of breast conserving treatments?].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2004
Same author

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2004
Same journal

The concept of functional cure in advanced/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab alone.

British journal of cancer·2026
Same journal

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

British journal of cancer·2026
Same journal

Altretamine induces ferroptosis in small cell lung cancer by promoting epigenetic silencing and lysosomal degradation of GPX4.

British journal of cancer·2026
Same journal

Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.

British journal of cancer·2026
Same journal

De novo cancer-related mortality after solid organ transplantation in England: the EpCOT study.

British journal of cancer·2026
Same journal

Planetary Health Diet Index and breast cancer risk.

British journal of cancer·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Oxaliplatin is a third-generation platinum complex used in cancer treatment.
  • It has shown activity in colorectal and advanced ovarian cancers.

Purpose of the Study:

  • To evaluate the safety and efficacy of oxaliplatin in cancer treatment.
  • To compare oxaliplatin with cisplatin in ovarian cancer therapy.

Main Methods:

  • Cohort study of 490 patients with advanced colorectal cancer.
  • Administration of oxaliplatin plus 5-fluorouracil (5-FU).
  • Comparison of oxaliplatin and cisplatin in combination with cyclophosphamide for ovarian cancer.

Main Results:

  • Oxaliplatin demonstrated a favorable safety profile with low hematotoxicity and manageable gastrointestinal toxicity.

Related Experiment Videos

  • Peripheral sensory neuropathy, a dose-limiting toxicity, is cold-induced and generally reversible.
  • Oxaliplatin showed similar efficacy to cisplatin in ovarian cancer but with better tolerability across multiple toxicity parameters.

    • Conclusions:

    • Oxaliplatin is a well-tolerated option for colorectal and ovarian cancers.
    • Its safety profile supports its use in combination chemotherapy regimens.